Protagonist Corp (PTGX) - Long-Term Debt to Capital Coefficient
Current price action for Protagonist Therapeutics (PTGX) reflects the performance of the company, which developed pill-based alternatives to injections under the leadership of Dinesh Patel. The business relies on the commercial implementation of peptide drugs, where the launch of rusfertide and royalties from J&J will serve as key growth drivers. The debt-to-equity ratio stands at 0.01, with finances based on tranches from counterparties rather than consistent product sales.
%20Long-Term%20Debt%20to%20Capital&width=1200&height=400&colorIndex=0&v=mvvwvvs9.gq-7b28iyo&start=20220704&end=20261030&filename=GURU_Markets_-_PTGX_-_Protagonist-Therapeutics_-_Long-Term-Debt-to-Capital "PTGX: Protagonist Long-Term Debt to Capital 07/04/2022 - 10/30/2026 | 👁️GURU.Markets👁️")
Comprehensive metric breakdowns and analytics for Protagonist Therapeutics (PTGX)
- stock price and consensus target price:
- market capitalization indicators:
- balance sheet net asset value indicators:
- debt and solvency information:
Total Debt to Equity Ratio Protagonist Therapeutics|PTGX - Long-Term Debt to Capital|Short-Term Debt to Capital protagonist-inc.com|PTGX - Company Total Debt|Debt to Net Assets Ratio Protagonist|PTGX - Company Long-Term Debts|Short-Term Debt Volume Protagonist Therapeutics|Quick Liquidity Indicator protagonist-inc.com
- net income and valuation ratios data:
General company analysis:Protagonist Therapeutics, Inc. - PTGX
This ratio determines the company's degree of dependence on debt with a maturity of over one year relative to its equity, reflecting the financial stability of the structure. By analyzing this long-term leverage, an investor sees the actual debt load, which for Protagonist Therapeutics (PTGX) is critical when financing the costly development of oral peptide drugs for the treatment of severe immune pathologies.
Key competitors
argenx N.V. - Long-Term Liabilities to Equity|Long-Term Debt to Capital BNTX|ABVX (Abivax S.A.) - Long-Term Debt to Capital Coefficient|Long-Term Debt to Capital ADMA (ADMA Biologics)|Long-Term Debt to Capital immunovant.com IMVT|KNSA - Long-Term Debt to Equity|Long-Term Debt to Capital Coefficient GRFS (Grifols SA)|Adaptive Biotechnologies Corp (ADPT) - Long-Term Debt to Equity|Long-Term Debt to Equity Ratio Celldex Corp|AUPH (Aurinia Pharmaceuticals) - Long-Term Debt to Capital|Long-Term Debt to Capital biocryst.com|Long-Term Debt to Equity Ratio VERA (Vera Therapeutics)|DNTH (Dianthus Therapeutics Inc) - Long-Term Debt to Capital Coefficient|Long-Term Debt to Capital PHVS (Pharvaris Corp)|Ratio of Long-Term Indebtedness to Capital AbCellera (ABCL)|TRML - Long-Term Debt to Equity|precigen.com (PGEN) - Long-Term Debt to Equity Ratio|Pharming Group (PHAR) - Long-Term Debt to Equity|Long-Term Debt to Equity Ratio Nektar Therapeutics Inc|Long-Term Debt to Equity Ratio UPB|Long-Term Debt to Capital Zenas Corp|Long-Term Debt to Equity Immunome, Inc. (IMNM)|gossamerbio.com - Long-Term Debt to Capital Ratio|Long-Term Debt to Capital KALV (KalVista Pharmaceuticals, Inc.)|Septerna, Inc. (SEPN) - Long-Term Liabilities to Capital|PVLA - Long-Term Debt to Equity|Long-Term Liabilities to Equity SVRA|Rigel Pharmaceuticals (RIGL) - Long-Term Debt to Equity|anaptysbio.com - Long-Term Debt to Capital Coefficient|Long-Term Debt to Equity Astria Therapeutics, Inc.|Long-Term Liabilities to Capital enGene Holdings Inc ENGN|Long-Term Debt to Equity Ratio RAPT (RAPT Therapeutics, Inc.)|Long-Term Loans to Capital Ratio JBIO|Long-Term Debt to Capital ACRS (Aclaris Therapeutics)|Long-Term Debt to Capital kyvernatx.com KYTX|Tiziana Life Sciences Ltd - Long-Term Debt to Capital|Long-Term Indebtedness to Equity Cabaletta Bio Inc. (CABA)|Ventyx Bio (VTYX) - Long-Term Debt to Equity|Long-Term Liabilities to Capital Theratechnologies, Inc (THTX)|Long-Term Debt to Equity Avalo Therapeutics, Inc|Long-Term Debt to Capital Ratio ELDN (eledon.com)|Long-Term Debt to Capital AGEN|Ratio of Long-Term Indebtedness to Capital Climb Bio Inc.|Long-Term Debt to Equity Zura Bio Limited ZURA|Ratio of Long-Term Indebtedness to Capital aTyr Pharmaceuticals (ATYR)|ADAG: Long-Term Debt to Equity Ratio|ImageneBio Inc - Long-Term Loans to Capital Ratio|STTK (shattucklabs.com) - Long-Term Debt to Equity Ratio|Equillium - Long-Term Debt to Capital Coefficient|Long-Term Debt to Equity Ratio CNTB|IMUX (Immunic Inc) - Long-Term Loans to Capital Ratio|Long-Term Debt to Capital ATRA|IFRX (inflarx.de) - Long-Term Debt to Capital Coefficient|Long-Term Debt to Capital XFOR (X4 Pharmaceuticals, Inc.)|Adicet Bio Inc. (ACET) - Long-Term Liabilities to Capital|CELU - Long-Term Debt to Equity|Long-Term Debt to Capital Coefficient INMB (INmune Bio Corporation)|BRNS: Long-Term Debt to Capital|kezarlifesciences.com (KZR) - Long-Term Debt to Capital|Long-Term Debt to Equity SAB Biotherapeutics, Inc.|Akari Therapeutics PLC - Long-Term Liabilities to Equity|Long-Term Debt to Capital ENLV|QTTB - Long-Term Liabilities to Capital|GeoVax Labs, Inc. - Long-Term Debt to Equity Ratio|Long-Term Debt to Capital edesabiotech.com EDSA|IBIO: Long-Term Debt to Equity Ratio|Carisma Therapeutics - Long-Term Loans to Capital Ratio|XTLB: Long-Term Debt to Capital|BOLT - Ratio of Long-Term Indebtedness to Capital|HCWB (HCW Biologics, Inc.) - Long-Term Debt to Capital|Long-Term Debt to Equity Ratio Aptevo (APVO)|Long-Term Debt to Equity AIM ImmunoTech (AIM)|Ratio of Long-Term Indebtedness to Capital aditxt.com|Long-Term Debt to Equity GRI Bio Corp GRI|XRTX (XORTX Corp) - Long-Term Liabilities to Equity|HIND: Long-Term Debt to Equity Ratio|revbiosciences.com - Long-Term Loans to Capital Ratio|INDP: Long-Term Debt to Capital|Long-Term Indebtedness to Equity Scinai Immunotherapeutics Ltd SCNI|Long-Term Debt to Equity Ratio CALI|Long-Term Debt to Capital Ratio AFMD (Affimed Therapeutics)|Long-Term Debt to Equity Allakos Inc. (ALLK)|HOOK: Long-Term Liabilities to Equity|Long-Term Debt to Capital IGMS (IGM Biosciences)|Long-Term Debt to Capital Coefficient ITOS|Ocean Bio - Long-Term Debt to Capital|TCBP - Long-Term Debt to Capital|Third Harmonic Bio (THRD) - Long-Term Debt to Equity